Viridian Therapeutics Announces Partnership With Drug Delivery Innovator Enable Injections
Viridian Therapeutics, Inc. recently announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse innovative wearable drug delivery system for volumes of up to 25 mL.
“As we expand our pipeline beyond TED and assess the unmet needs of patients living with other serious and rare diseases, it’s clear that convenient drug delivery is an important issue,” said Scott Myers, President and CEO of Viridian. “We believe Enable’s proprietary technology can contribute meaningfully to our goal of delivering therapeutic advances while reducing patient treatment burden as well.”
“Enable Injections is excited to partner with Viridian to utilize the enFuse technology to enhance the patient experience,” said Michael D. Hooven, Enable Injections’ Chairman and CEO. “The enFuse on-body delivery system was engineered with the patient in mind—the hidden needle and hands-free delivery allows patients to have increased flexibility, improved convenience, and the ability to administer medication discreetly, whether at home via self-administration or in the clinic.”
This partnership, which applies exclusively to areas outside of Viridian’s established TED portfolio, underscores the company’s commitment to patient-centric innovation.
Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company has initiated its first global Phase 3 trial called THRIVE to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its program for intravenously administered VRDN-001, the company is advancing three candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is also developing multiple preclinical assets in autoimmune and rare diseases. Viridian is based in Waltham, MA. For more information, visit www.viridiantherapeutics.com.
Cincinnati-based Enable Injections is a global healthcare innovation company developing and manufacturing drug delivery systems designed to improve the patient experience. Enable’s body-worn enFuse delivers high-volume pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. The investigational enFuse system has not been approved for use by any regulatory agency and is currently not approved for commercial use. For more information, visit www.enableinjections.com.
Total Page Views: 1269
